Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years

Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line Kesimpta (ofatumumab) treatment for up to six years led to less disability and disease progression in recently diagnosed (≤3 years) and treatment-naïve (RDTN) people with relapsing multiple sclerosis (RMS), compared to those who switched from Sanofi SA’s (NASDAQ:SNY) Aubagio (teriflunomide). These data will be presented at the European Committee for Treatment and Research in Multiple Sclerosis. Also Read: Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts. Data from the overall ALITHIOS study population showed ...